Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.34 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.34 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408945 | 0.84 | LIPE (0.33) | ATMENPP2 | |
| SCHEMBL407984 | 0.79 | ENPP2 (0.35) | ATMEPHX2ENPP2 | |
| SCHEMBL408780 | 0.79 | ENPP2 (0.35) | ATMEPHX2ENPP2 | |
| SCHEMBL407401 | 0.73 | EPHX2 (0.34) | EPHX2 | |
| SCHEMBL407409 | 0.72 | TLR8 (0.40) | — | |
| Bromide SCHEMBL437843 | 0.71 | TLR8 (0.39) | — | |
| SCHEMBL441068 | 0.69 | PKM (0.37) | EPHX2ENPP2 | |
| SCHEMBL17911333 | 0.69 | EPHX2 (0.35) | EPHX2ENPP2 | |
| SCHEMBL15490002 | 0.69 | CYP2C19 (0.41) | ATM | |
| SCHEMBL407920 | 0.68 | KDM1A (0.33) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | GRIA1 478/4885GRIA2 417/4885GRIA3 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.